Thomas Jefferson University in Philadelphia, PA and NuView Life Sciences have entered into an exclusive licensing agreement for advancing the development of a new molecular imaging compound which identifies genomic expressions linked to prostate cancer.
Read MoreResearchers believe that genetics and traditional screening methods could play a role in predicting the risk of prostate cancer in younger men.
Read More
This month’s cover story on mass spectrometry for the clinical lab is the first CLP has published on this topic, but I don’t believe it will be our last. According to sources at the FDA and the National Cancer Institute’s proteomics prog
Read More
As diagnostics come to depend on increasingly sophisticated knowledge of biomarkers, mass spec emerges as a tool with revolutionary potential.
Read More
BioImagene
Read More